[{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"b8938d92-36d0-423c-9eba-e8257f8d60ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03799744","created_at":"2021-01-18T18:46:56.979Z","updated_at":"2025-02-25T15:08:14.577Z","phase":"Phase 1","brief_title":"Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03799744","lead_sponsor":"Institut Català d'Oncologia","biomarkers":" IL6 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2022-03-28"},{"id":"6374d5b8-2750-44ab-ba42-28d9cdad5981","acronym":"","url":"https://clinicaltrials.gov/study/NCT04058964","created_at":"2021-01-18T19:53:43.999Z","updated_at":"2024-07-02T16:36:48.674Z","phase":"Phase 2","brief_title":"Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04058964","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pegvorhyaluronidase alfa (PEGPH20)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2020-03-13"},{"id":"5c5aa4fc-2e85-4ffd-8e85-4c95af2d9d45","acronym":"","url":"https://clinicaltrials.gov/study/NCT02563548","created_at":"2021-01-18T12:24:47.140Z","updated_at":"2024-07-02T16:36:50.341Z","phase":"Phase 1b","brief_title":"A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors","source_id_and_acronym":"NCT02563548","lead_sponsor":"Halozyme Therapeutics","biomarkers":" PD-L1 • ALK • PD-1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["PD-L1 • ALK • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pegvorhyaluronidase alfa (PEGPH20)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 10/22/2015","start_date":" 10/22/2015","primary_txt":" Primary completion: 03/26/2019","primary_completion_date":" 03/26/2019","study_txt":" Completion: 03/26/2019","study_completion_date":" 03/26/2019","last_update_posted":"2020-02-07"},{"id":"ec3fc90f-0d12-4e9a-99b7-365eca56815f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01453153","created_at":"2021-01-18T06:01:57.218Z","updated_at":"2024-07-02T16:37:04.970Z","phase":"Phase 1b/2","brief_title":"Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer","source_id_and_acronym":"NCT01453153","lead_sponsor":"Halozyme Therapeutics","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • pegvorhyaluronidase alfa (PEGPH20)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2018-11-30"}]